EML2-AS1: A Potential Drug Target and Biomarker (G100287177)

Target Name: EML2-AS1

NCBI ID: G100287177

EML2-AS1

Other Name(s): C19orf83 | EML2 antisense RNA 1 | EML2-AS1 variant 1

EML2-AS1: A Potential Drug Target and Biomarker

EML2-AS1, also known as ESI-122, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the EML family of proteins, which are involved in the regulation of cell proliferation and differentiation. The EML2-AS1 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target

EML2-AS1 has been shown to play a role in the regulation of cellular proliferation and has been linked to the development and progression of various diseases. One of the most significant findings related to EML2-AS1 is its role in the development of cancer. EML2-AS1 has been shown to promote the growth and survival of cancer cells, and it has been used as a potential drug target for cancer treatment.

Studies have shown that EML2-AS1 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to promote the migration and invasion of cancer cells, which can contribute to the development of invasive and metastatic cancers. Therefore, targeting EML2-AS1 with drugs that can inhibit its function could be an effective way to treat cancer.

Biomarker

EML2-AS1 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression has been shown to be associated with the development and progression of cancer, and it has been used as a biomarker for cancer diagnosis and monitoring.

One of the most significant applications of EML2-AS1 as a biomarker is its ability to be used as a target for cancer immunotherapy. Cancer immunotherapy involves the use of antibodies or other immune cells to target and destroy cancer cells. EML2-AS1 has been shown to be a good candidate for cancer immunotherapy due to itsexpression in various tissues of the body and its ability to be targeted with antibodies.

In addition to its potential as a cancer immunotherapy, EML2-AS1 has also been shown to be a potential biomarker for other diseases, including neurodegenerative diseases and autoimmune disorders. Its expression has been shown to be associated with the development and progression of these diseases, and it has been used as a biomarker for their diagnosis and monitoring.

Conclusion

EML2-AS1 is a protein that has been shown to play a role in the regulation of cellular proliferation and has been linked to the development and progression of various diseases. Its potential as a drug target and biomarker make it an attractive target for research into the treatment of cancer and other diseases. Further studies are needed to fully understand the role of EML2-AS1 in disease and to develop effective treatments based on its properties.

Protein Name: EML2 Antisense RNA 1

The "EML2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EML2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets